Loading patent…
AssigneeBristol-Myers Squibb Company
InventorKoustubh Ranade
Estimating the term…
The invention provides novel polynucleotides and polypeptides associated with the incidence of PPAR-agonist induced congestive heart failure. The invention also provides polynucleotide fragments corresponding to the genomic and/or coding regions of these polynucleotides which comprise at least one polymorphic locus per fragment. Allele-specific primers and probes which hybridize to these regions, and/or which comprise at least one polymorphic locus are also provided. The polynucleotides, primers, and probes of the present invention are useful in phenotype correlations, medicine, and genetic analysis. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel polynucleotides and polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders, particularly PPAR-agonist induced congestive heart failure or related indications.
An isolated nucleic acid molecule comprising a polynuclelotide sequence selected from the group consisting of the polynucleotide sequence provided as SEQ ID NO:1, 3, 13, 15, 26, and 28.
A method of identifying a patient who may be at risk of developing dose-dependent congestive heart failure upon administration of a PPAR-agonist comprising the step of determining whether said patient has a reference or variable allele at one or more polymorphic loci of the human mineralocorticoid gene.
A method of identifying a patient who may be at risk of developing dose-dependent congestive heart failure upon administration of a PPAR-agonist comprising the step of determining whether said patient has a reference or variable allele at one or more polymorphic loci of the human PPAR-gamma gene.
A method of identifying a patient who may be at risk of developing dose-dependent congestive heart failure upon administration of a PPAR-agonist comprising the step of determining whether said patient has a reference or variable allele at one or more polymorphic loci of the human adiponectin gene.
An isolated polypeptide comprising a sequence selected from the group consisting of the polypeptide sequence provided as SEQ ID NO:2, and SEQ ID NO:4, wherein said polypeptide comprises at least one polymorphic locus, wherein said polymorphic locus is located at amino acid position 180.
A method of identifying a patient who may be at risk of developing dose-dependent congestive heart failure upon administration of a PPAR-agonist comprising the step of determining whether said patient has a reference or variable allele at one or more polymorphic loci of the human mineralocorticoid receptor polypeptide.
An isolated polypeptide comprising a sequence selected from the group consisting of the polypeptide sequence provided as SEQ ID NO:14, and SEQ ID NO:16, wherein said polypeptide comprises at least one polymorphic locus, wherein said polymorphic locus is located at amino acid position 180.
A method of identifying a patient who may be at risk of developing dose-dependent congestive heart failure upon administration of a PPAR-agonist comprising the step of determining whether said patient has a reference or variable allele at one or more polymorphic loci of the human PPAR-gamma polypeptide.
An isolated polypeptide comprising a sequence selected from the group consisting of the polypeptide sequence provided as SEQ ID NO:27, and SEQ ID NO:29, wherein said polypeptide comprises at least one polymorphic locus, wherein said polymorphic locus is located at amino acid position 111.
A method of identifying a patient who may be at risk of developing dose-dependent congestive heart failure upon administration of a PPAR-agonist comprising the step of determining whether said patient has a reference or variable allele at one or more polymorphic loci of the human adiponectin polypeptide.
Dependencies are inferred from the claim text.